Swapnil Bhargava
Technik-/Wissenschafts-/F&E-Leiter bei CG ONCOLOGY, INC.
Profil
Swapnil Bhargava is currently the Chief Technical Officer at CG Oncology, Inc. He previously worked as the SVP-CMC Development & GMP Manufacturing at AbCellera Biologics, Inc. and as the VP-Drug Substance Process Development at Seagen Inc. Dr. Bhargava holds a doctorate degree from the University of Maryland and a graduate degree from the Indian Institute of Technology Delhi.
Aktive Positionen von Swapnil Bhargava
| Unternehmen | Position | Beginn |
|---|---|---|
| CG ONCOLOGY, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.09.2023 |
Ehemalige bekannte Positionen von Swapnil Bhargava
| Unternehmen | Position | Ende |
|---|---|---|
| SEAGEN INC. | Corporate Officer/Principal | - |
| ABCELLERA BIOLOGICS INC. | Corporate Officer/Principal | - |
Ausbildung von Swapnil Bhargava
| University of Maryland | Doctorate Degree |
| Indian Institute of Technology Delhi | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| CG ONCOLOGY, INC. | Health Technology |
| ABCELLERA BIOLOGICS INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Seagen Inc.
 Seagen Inc. Pharmaceuticals: MajorHealth Technology Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. | Health Technology |
